Sanofi in talks to sell 50% stake in consumer health business to CD&R
Adds French finance ministry comments in paragraphs 7-9
PARIS, Oct 11 (Reuters) -Sanofi SASY.PA has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice, the French pharmaceutical group said on Friday.
The announcement confirms an earlier Reuters report that it was closing in on a sale estimated at around 15 billion euros ($16.41 billion).
Sanofi did not disclose any financial details of the potential deal, and said further updates would be provided in due course. Shares in the group were down 0.46% at 0717 GMT.
The company said in October 2023 that it was reviewing potential scenarios to separate out its consumer healthcare business, as it seeks to shore up new drug development spending at its core business
In September, Bloomberg reported that Sanofi had received a bid from CD&R as well as from French rival PAI Partners for the Opella business.
Opella employs more than 11,000 people and owns brands like the painkiller Doliprane, popular in its home market.
The French finance ministry said in a statement that CD&R was a "serious investment fund" with positive prospects for Opella's development and its plants in France.
It added that it would require economic commitments from Sanofi and CD&R including guaranteeing that the business's headquarters and decision-making centres would remain in France, and protection of its industrial footprint in the country.
"This proposed sale does not call into question the production in France of Doliprane or other essential medicines produced by Opella on our territory, nor the supply of these medicines to the market. This is naturally part of the commitments requested," it added.
Rival Johnson & Johnson JNJ.N hived off its consumer health business Kenvue KVUE.N in May last year, while GSK GSK.L and Pfizer PFE.N spun off their consumer divisions in 2022.
($1 = 0.9143 euros)
Reporting by Piotr Lipinski and Dominique Patton; Editing by Jan Harvey and Jane Merriman
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
